Venture Capital Access Online | Venture Capital News
Summary
The funds will be used to conduct research to advance the Tesseract iC platform, accelerate the companys push to obtain US and international regulatory clearances, and ramp up manufacturing. The Tesseract iC platform is a binocular eye imaging device that is portable, affordable, and operable by anyone, supporting a post COVID world focused on cloud-connected telemedicine. Tesseract plans to usher in a new branch of diagnostics fusing the best of imaging and laboratory medicine, a truly worlds first to support screening, diagnosis, monitoring and treatment in a number of clinical domains to go well beyond ophthalmology to primary care, cardiology, neurology and more. With Tesseracts device, we believe they will. "We are excited about the potential of the Tesseract iC to combine a portable, non-invasive view of the eye with advances in AI," said Jim Tananbaum, CEO and Managing Director of Foresite Capital. We are pleased to co-invest with Jonathan and the Tesseract team to advance the development of its innovative retinal imaging platform, said Larry Robbins, CEO of Glenview Capital.